Target intelligence / Profile preview

Tumor-specific neoantigen peptide-HLA complexes (neoantigen-HLA)

Target
neoantigen-HLA
Molecular classification
Other
01

Overview

Tumor-specific neoantigen peptide-HLA complexes represent a highly personalized class of therapeutic targets on melanoma and other cancer cells. These complexes are formed when somatic mutations unique to a patient's tumor (neoantigens) are processed intracellularly and presented on the cell surface by human leukocyte antigen (HLA) molecules. Because these neoantigens are entirely absent from normal tissues, targeting these complexes minimizes the risk of on-target, off-tumor toxicities, making them ideal candidates for precision immunotherapy.

Therapeutic strategies targeting these complexes include individualized cancer vaccines (such as mRNA-4157/V940 and autogene cevumeran/BNT122) that train the patient's immune system to recognize these specific peptide-HLA presentations. Additionally, adoptive cell therapies, such as NeoTCR-P1, utilize CRISPR-engineered autologous T cells expressing T-cell receptors (TCRs) specifically cloned to bind these patient-specific neoantigen-HLA complexes. Clinical trials in melanoma have demonstrated that targeting these complexes can induce robust, durable de novo T-cell responses, leading to significant improvements in recurrence-free and distant metastasis-free survival when combined with immune checkpoint inhibitors.

Other names
Tumor-specific neoantigen peptide-HLA complexes on melanoma cellsNeoantigen-MHC complexesTumor-specific neoantigen peptide-MHC complexesNeoantigen peptide-HLA complexesMutational neoantigen peptide-HLA complexesTumor-specific antigen peptide-HLA complexes
02

Mechanism of action

Individualized neoantigen therapies (such as mRNA vaccines) encode patient-specific tumor neoantigens that are translated and presented as peptide-HLA complexes to stimulate endogenous T-cell responses, while adoptive TCR-T therapies utilize engineered T cells expressing TCRs that directly bind and destroy cells presenting these complexes.

03

Biological functions

Immune responseAntigen presentation
04

Disease associations

CancerMelanoma
05

Safety considerations

Cytokine release syndrome (CRS)Immune-related adverse events (irAEs)EncephalitisAntigen escape or HLA downregulationInjection site reactions and systemic flu-like symptoms
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Tumor mutational burden (TMB)HLA genotypeNeoantigen-specific T-cell frequencyCirculating tumor DNA (ctDNA)PD-L1 expression

Beyond the preview

Go deeper on Tumor-specific neoantigen peptide-HLA complexes (neoantigen-HLA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor-specific neoantigen peptide-HLA complexes (neoantigen-HLA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call